Outcomes of patients with AML after UCB transplantation based on the presence or absence of NK-cell alloreactivity in the GVHD direction
| Outcome . | Myeloablative conditioning . | Reduced-intensity conditioning . | ||||
|---|---|---|---|---|---|---|
| KIR-L mismatched, n = 18 . | KIR-L matched, n = 42 . | P . | KIR-L mismatched, n = 8 . | KIR-L matched, n = 20 . | P . | |
| Grade II-IV GVHD, % (95% CI) | 50 (26-74) | 38 (23-53) | .59 | 75 (45-100) | 50 (27-73) | .07 |
| Grade III-IV GVHD, % (95% CI) | 28 (8-48) | 17 (6-28) | .36 | 38 (8-68) | 5 (0-14) | .03 |
| Chronic GVHD at 1 year, % (95% CI) | 6 (0-16) | 26 (12-40) | .13 | 13 (0-33) | 24 (4-44) | .76 |
| TRM at 2 years, % (95% CI) | 22 (2-42) | 18 (6-28) | .49 | 25 (0-53) | 5 (0-14) | .08 |
| Relapse at 2 years, % (95% CI) | 30 (8-52) | 21 (8-34) | .29 | 50 (16-84) | 53 (29-77) | .49 |
| Survival at 3 years, % (95% CI) | 44 (18-68) | 66 (48-79) | .15 | 21 (1-59) | 54 (27-75) | .26 |
| Outcome . | Myeloablative conditioning . | Reduced-intensity conditioning . | ||||
|---|---|---|---|---|---|---|
| KIR-L mismatched, n = 18 . | KIR-L matched, n = 42 . | P . | KIR-L mismatched, n = 8 . | KIR-L matched, n = 20 . | P . | |
| Grade II-IV GVHD, % (95% CI) | 50 (26-74) | 38 (23-53) | .59 | 75 (45-100) | 50 (27-73) | .07 |
| Grade III-IV GVHD, % (95% CI) | 28 (8-48) | 17 (6-28) | .36 | 38 (8-68) | 5 (0-14) | .03 |
| Chronic GVHD at 1 year, % (95% CI) | 6 (0-16) | 26 (12-40) | .13 | 13 (0-33) | 24 (4-44) | .76 |
| TRM at 2 years, % (95% CI) | 22 (2-42) | 18 (6-28) | .49 | 25 (0-53) | 5 (0-14) | .08 |
| Relapse at 2 years, % (95% CI) | 30 (8-52) | 21 (8-34) | .29 | 50 (16-84) | 53 (29-77) | .49 |
| Survival at 3 years, % (95% CI) | 44 (18-68) | 66 (48-79) | .15 | 21 (1-59) | 54 (27-75) | .26 |
A P value less than .05 is shown in bold for easy identification.
AML indicates acute myeloid leukemia; UCB, umbilical cord blood; NK, natural killer; GVHD, graft-versus-host disease; KIR-L, killer-cell immunoglobulin–like receptor ligand; and TRM, treatment-related mortality.